Actionable news
All posts from Actionable news
Actionable news in APPY: Venaxis, Inc.,

Cantor Reiterates Buy on Endocyte, Inc. Following Vintafolide Clinical Update

In a research report published today, Cantor analyst Daniel Brims reiterated a Buy rating on shares of Endocyte, Inc. (NASDAQ:ECYT) with a price target of $21, after the company presented updated data from vintafolide’s Phase II TARGET trial at the World Conference on Lung Cancer. The analyst believes that vintafolide has demonstrated proof-of-concept for the small molecule drug conjugate platform, and potential can be realized with the second-generation drug, EC1456, due to apparent...